8-K filed Aug 11, 2026 at 17:04 ET
FocalTherics (formerly EDAP TMS) reported preliminary Q2 2026 HIFU revenue of $12.7M-$13.2M (+34-39% YoY), a record quarter, and announced the classification of its legacy ESWL and Distribution segments as discontinued operations, effectively becoming a pure-play robotic focal therapy company. The company also provided updates on its pipeline expansion into BPH and endometriosis, and highlighted a proposed +11.6% Medicare payment increase for HIFU in 2027. The strong preliminary results and strategic refocusing are positive, but the lack of full financials (EPS, operating cash flow) and the ongoing operating losses temper the bullishness.